Document Detail


Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction.
MedLine Citation:
PMID:  20225200     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic heart rate reduction (HRR) therapy following myocardial infarction, using either the pure HRR agent ivabradine or the beta-blocker atenolol, has been shown to preserve maximal coronary perfusion, via reduction of perivascular collagen and a decrease in renin-angiotensin system activation. In addition ivabradine, but not atenolol, treatment attenuated the decline in ejection fraction and decreased left ventricular wall stress. In this study, we tested the hypothesis that cell survival within the infarct region was enhanced by these two pharmacological agents. Four weeks after ligating the left anterior descending coronary artery, the percentage of the LV that contained the infarct was similar in the untreated (MI) rats and those chronically treated with ivabradine (MI + IVA) or atenolol (MI + ATEN). However, the mean thickness (mm) of the ventricular wall containing the scar was significantly greater in the MI + IVA, 1.54 (P < or = 0.01) and the MI + ATEN 1.32, compared to 1.1 in the MI group, due to a 2-fold greater area of surviving cardiomyocytes (P < or = 0.01) in the treated rats compared to the untreated group. Regions of cell survival were usually in the subepicardium, with cardiomyocytes surrounding veins or venules. However, some hearts displayed surviving cells along the endocardium. These data suggest that HRR by either ivabradine or atenolol facilitates a more favorable O2 microenvironment via improved venous flow and decreased O2 demand. We conclude that chronic HRR by these agents may serve to limit infarct expansion and wall thinning and may serve to reduce the potential for ventricular rupture.
Authors:
Rong-Lin Zhang; Lance P Christensen; Robert J Tomanek
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anatomical record (Hoboken, N.J. : 2007)     Volume:  293     ISSN:  1932-8494     ISO Abbreviation:  Anat Rec (Hoboken)     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-30     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101292775     Medline TA:  Anat Rec (Hoboken)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  839-48     Citation Subset:  IM    
Affiliation:
Department of Anatomy and Cell Biology, University of Iowa, Iowa City, Iowa, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Arrhythmia Agents / pharmacology,  therapeutic use
Atenolol / pharmacology*,  therapeutic use
Benzazepines / pharmacology*,  therapeutic use
Bradycardia / chemically induced
Cell Survival / drug effects,  physiology
Cicatrix / drug therapy,  physiopathology
Coronary Circulation / drug effects,  physiology
Diastole / drug effects,  physiology
Disease Models, Animal
Heart Rate / drug effects*,  physiology
Male
Myocardial Infarction / drug therapy*,  pathology,  physiopathology
Myocardium / cytology,  metabolism
Myocytes, Cardiac / cytology,  drug effects*,  physiology
Rats
Rats, Sprague-Dawley
Recovery of Function / drug effects*,  physiology
Regeneration / drug effects,  physiology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Benzazepines; 155974-00-8/ivabradine; 29122-68-7/Atenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluore...
Next Document:  Possible mechanisms of trichosanthin-induced apoptosis of tumor cells.